DCM
KZR

Driehaus Capital Management’s Kezar Life Sciences KZR Stock Holding History

Driehaus Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,000
Closed -$932K – 420
2020
Q2 		$932K Buy
+18,000
New +$908K 0.02% 288

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Driehaus Capital Management's KZR Position: Q3 2020 in Review

Driehaus Capital Management sold out of Kezar Life Sciences (KZR) in Q3 2020, closing a stake of 18,000 shares — an estimated $932K sold.

Driehaus Capital Management first reported a position in KZR in Q2 2020 and held it in 1 quarter. The position peaked at $932K in Q2 2020. 78 funds tracked by Wall St. Rank hold KZR as of Q3 2020.

  • Driehaus Capital Management reported no remaining Kezar Life Sciences position as of Q3 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 18,000 Kezar Life Sciences shares in Q3 2020, an estimated $932K.
  • Driehaus Capital Management first reported a position in Kezar Life Sciences in Q2 2020 and held it in 1 quarter.
  • Driehaus Capital Management's Kezar Life Sciences position peaked at $932K in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2020.

Based on Driehaus Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.